Positive results with Endocine™ and a vaccine candidate against COVID-19
STOCKHOLM, Sept. 23, 2021 /PRNewswire/ -- The first preclinical study, where the adjuvant technology Endocine™ has been evaluated with a vaccine candidate against COVID-19, shows positive results.
In May 2021, Eurocine Vaccine signed an evaluation agreement with an innovative North American company with the ambition to evaluate Endocine™ along with their vaccine candidate against COVID-19.
The first study in a mouse model indicates positive results with our adjuvant Endocine™, where antibodies of both type IgA and IgG could be detected, as well as T cell immunity.
The North American company now intends to proceed with additional studies where Eurocine Vaccines will deliver Endocine™ and assist with knowledge and experience within the area.
Read more about our adjuvant:
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
+46 70 634 0171
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Positive results with Endocineâ„¢ and a vaccine candidate against COVID-19
Upcoming Life Sciences Events
- October 2021
- BIO-Europe® 2021
- Online: AusBiotech 2021 & Australia Biotech Invest & Partnering
- November 2021
- Pharma-Biotech Product & Company Valuation with Dr. P Frei
Latest company news
There are currently no news available for this portal